Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer

Human Pathology

Volumn 41, Issue 1, 2010, Pages 103-106

  Shah, Sejal S ^a   Ketterling, Rhett P ^a   Goetz, Matthew P ^a   Ingle, James N ^a   Reynolds, Carol A ^a   Perez, Edith A ^b   Chen, Beiyun ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Breast carcinoma; FISH; HER2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER INVASION; CELL HETEROGENEITY; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MEDICAL SOCIETY; PRACTICE GUIDELINE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL COUNT; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MEDICAL ONCOLOGY; NEOPLASM INVASIVENESS; PATHOLOGY, CLINICAL; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 71049124846     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.07.001     Document Type: Article

References (29)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
2. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
3. Offersen B.V., Alsner J., Ege Olsen K., et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 47 (2008) 618-632
4. Winstanley J., Cooke T., Murray G.D., et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63 (1991) 447-450
5. Andrulis I.L., Bull S.B., Blackstein M.E., et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16 (1998) 1340-1349
6. Gullick W.J., Love S.B., Wright C., et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63 (1991) 434-438
7. Carr J.A., Havstad S., Zarbo R.J., Divine G., Mackowiak P., and Velanovich V. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg 135 (2000) 1469-1474
8. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
9. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
10. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
11. Hayes D.F., and Picard M.H. Heart of darkness: the downside of trastuzumab. J Clin Oncol 24 (2006) 4056-4058
12. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131 (2007) 18
13. Lal P., Salazar P.A., Hudis C.A., Ladanyi M., and Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 121 (2004) 631-636
14. Wang S., Saboorian M.H., Frenkel E., Hynan L., Gokaslan S.T., and Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 53 (2000) 374-381
15. McCormick S.R., Lillemoe T.J., Beneke J., Schrauth J., and Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 117 (2002) 935-943
16. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., and Schnitt S.J. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17 (1999) 1974-1982
17. Ridolfi R.L., Jamehdor M.R., and Arber J.M. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13 (2000) 866-873
18. Lebeau A., Deimling D., Kaltz C., et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19 (2001) 354-363
19. Persons D.L., Borelli K.A., and Hsu P.H. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10 (1997) 720-727
20. Pauletti G., Godolphin W., Press M.F., and Slamon D.J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13 (1996) 63-72
21. Hoang M.P., Sahin A.A., Ordòñez N.G., and Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113 (2000) 852-859
22. Lal P., Salazar P.A., Ladanyi M., and Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 5 (2003) 155-159
23. Varshney D., Zhou Y.Y., Geller S.A., and Alsabeh R. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 121 (2004) 70-77
24. Lewis J.T., Ketterling R.P., Halling K.C., Reynolds C., Jenkins R.B., and Visscher D.W. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 124 (2005) 273-281
25. Striebel J.M., Bhargava R., Horbinski C., Surti U., and Dabbs D.J. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Am J Clin Pathol 129 (2008) 383-390
26. Dastane A.M., Alsabeh R., and Bose S. Effect of ASCO/CAP Recommended Guideline for Positive Her2/neu Stain on FISH Concordance-an evidence based study. Mod Pathol 28A (2008) 21
27. Gilmore H.L., Collins L.C., Connolly J.L., and Schnitt S.J. Impact of the New American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guidelines on the Determination of Breast Cancer HER2 Status. Mod Pathol 32A (2008) 21
28. Paik S., Kim C., and Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358 (2008) 1409-1411
29. Perez E.A., Romond E.H., Suman V.J., et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 25 18S (2007) 512